1-2 of 2
Vishwanath Gharpure
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Nicola Vianelli, Giulia Benevolo, Alessandro Vannucchi, Claire N. Harrison, Michael Loschi, Haifa Kathrin Al-Ali, Massimiliano Bonifacio, Francisco Cervantes, Tomasz Wrobel, Giovanni Barosi, Jean-Jaques Kiladjian, Srdan Verstovsek, Ruben A. Mesa, Shelonitda Rose, Vishwanath Gharpure, Christopher Hernandez, Jun Zhang, Francesco Passamonti
Journal: Blood
Blood (2021) 138 (Supplement 1): 3643.
https://doi.org/10.1182/blood-2021-147614
Published: 2021
Journal Articles

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben A. Mesa, Claire N. Harrison, Giovanni Barosi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Vishwanath Gharpure, Christopher Hernandez, Tianhua Wang, Moshe Talpaz
Journal: Blood
Blood (2021) 138 (Supplement 1): 389.
https://doi.org/10.1182/blood-2021-147607
Published: 2021